Tarlatamab (AMG 757), a bispecific T‐cell engager combining DLL3 and CD3, can induce T‐cell‐mediated tumour lysis, increase the number of effector T‐cells near the tumour and enhance anti‐tumour effects. Here, DLL3 is linked to neoplasm.